Aclaris Therapeutics (ACRS) vs ArriVent BioPharma (AVBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 37.1% versus a loss of 48.3%. Aclaris Therapeutics is the larger company by market cap ($545.6 million vs $544.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | AVBP |
|---|---|---|
| Share price | $3.44 | $10.52 |
| Market cap | $545.63M | $544.13M |
| 1-day change | -1.71% | -6.57% |
| YTD return | +14.29% | -47.71% |
| 1-year return | +37.05% | -48.30% |
| 5-year return | -72.74% | — |
| EPS (TTM) | $-0.59 | $-3.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.83M | — |
| Revenue growth (YoY) | -58.19% | — |
| Net income (latest FY) | $-64.92M | $-166.31M |
| Gross margin | 73.28% | — |
| Operating margin | -975.91% | — |
| Net margin | -829.58% | — |
| 52-week high | $6.60 | $35.83 |
| 52-week low | $2.46 | $10.33 |
| Distance from 52-week high | -47.88% | -70.64% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +205.23% | +149.05% |
| Average volume | 3.07M | 1.37M |
| Shares outstanding | 158.61M | 51.72M |
| Employees | 69 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed AVBP by 85.4 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
ACRS vs AVBP FAQ
Which is bigger, Aclaris Therapeutics or ArriVent BioPharma?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $545.63M compared with $544.13M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, ACRS or AVBP?
ACRS returned +37.05% over the past 12 months, compared with -48.30% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and ArriVent BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.